The deal includes Caplyta, a treatment for schizophrenia and bipolar depression, along with a pipeline focused on disorders such as generalized anxiety and Alzheimer’s-related psychosis, according to an Jan. 13 news release from the company.
The acquisition bolsters J&J’s neuroscience portfolio, with Caplyta expected to generate more than $5 billion in peak annual sales. It also strengthens the company’s position in central nervous system therapies, including ongoing Phase 3 trials for bipolar mania and schizophrenia relapse prevention, the release said.
The deal is expected to close later in 2025, pending regulatory approval.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.